FOLH1 and pachyonychia congenita: Recently, the Society for Nuclear Medicine and Molecular Imaging and the National Comprehensive Cancer Network have recommended PSMA PET for the initial staging of patients with unfavorable intermediate-, high-, and very high–risk clinically localized PC, as well as for patients with biochemically recurrent PC (12,13).